Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Tetramic acid" patented technology

Tetramic acids with polyenyl substituents are an important class of compounds in medicinal chemistry. Both solid and solution phase syntheses of such molecules have been reported recently.

Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and/or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.
Owner:CHILDRENS HOSPITAL OF LOS ANGELES +1

Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and / or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.
Owner:CHILDRENS HOSPITAL OF LOS ANGELES +1

New trifluoromethoxy-phenyl substituted tetramic acid-derivatives useful to combat parasites including insects, arachnid, helminth, nematode and mollusk and/or undesirable plant growth and in hygienic sectors

Trifluoromethoxy-phenyl substituted tetramic acid-derivatives (I), are new. Trifluoromethoxy-phenyl substituted tetramic acid-derivatives of formula (I), are new. J1a : trifluoromethoxy; X : H, alkyl, halo, haloalkyl, alkoxy or haloalkoxy; Y1a : H, alkyl or halo, where at least one of J1a, X or Y1a is present at position-2 of the phenyl residue and is at the same time unequally hydrogen; either A : alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, optionally saturated cycloalkyl (all optionally substituted by halo and at least a ring atom is optionally substituted by a heteroatom), aryl, arylalkyl, hetaryl (all optionally substituted by halo, (halo)alkyl, (halo)alkoxy, cyano or nitro) or H; and B1a : H or alkoxyalkyl; and D : H or a residue optionally substituted by alkyl, alkenyl, alkynyl, alkoxyalkyl, optionally saturated cycloalkyl, in which optionally one or more ring members are substituted by heteroatom, arylalkyl, aryl, hetarylalkyl or hetaryl; or C+A+B1a : optionally saturated, substituted and heteroatom containing cyclic group; or A+D : optionally saturated and at least a heteroatom containing, in A, D-parts optionally substituted cyclic group; G : H, carboxy group of formula (-CO-R 1>) or (-C(=L)-M-R 2>), sulfur dioxide group of formula (-SO 2-R 3>), phosphorus group of formula (-P(R 4>)(R 5>)(=L)), E or (-C(=L)-N(R 6>)(R 7>)); E : an equivalent metal ion or an ammonium ion; L, M : O or S; R 1>optionally halo substituted alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl or polyalkoxyalkyl, optionally halo-, alkyl- or alkoxy substituted cycloalkyl, which is interrupted by at least a heteroatom, optionally substituted phenyl, phenylalkyl, hetaryl, phenoxyalkyl or hetaryloxyalkyl; R 2>optionally halo substituted alkyl, alkenyl, alkoxyalkyl or polyalkoxyalkyl, optionally substituted cycloalkyl, phenyl or benzyl; R 3>-R 5>optionally halo substituted alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenylthio or cycloalkylthio, or optionally substituted phenyl, benzyl, phenoxy or phenylthio; and either R 6>, R 7>optionally halo substituted alkyl, cycloalkyl, alkenyl, alkoxy or alkoxyalkyl, optionally substituted phenyl or benzyl, or H; or NR 6>R 7>cyclic group interrupted optionally by O or S. Independent claims are included for: (1) the preparation of (I); (2) the preparation of an agent to combat parasite and / or undesirable plant growth comprising mixing (I) with a diluent and / or a surface active material; (3) an agent comprising an active agent combination containing (I), at least a compound, which improves the compatibility of cultured plants, e.g. 4-dichloroacetyl-1-oxa-4-aza-spiro[4.5]-decane, 1-dichloroacetyl-hexahydro-3,3,8a-trimethylpyrrolo[1,2-a]-pyrimidin-6 (2H)-one, 4-dichloroacetyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazine, 5-chloro-quinolin-8-oxy-acetic acid-(1-methyl-hexylester), 3-(2-chloro-benzyl)-1-(1-methyl-1-phenyl-ethyl)-urea, alpha -(cyanomethoxyimino)-phenylacetonitrile, diethyl-1-(2,4-dichloro-phen yl)-4,5-dihydro-5-methyl-1H-pyrazol-3,5-dicarboxylate, 2-dichloromethyl-2-methyl-1,3-dioxolane, 2-propenyl-1-oxa-4-azaspiro[ 4.5]decane-4-carbodithioate, 1,8-naphthalic acid anhydride, 1-(2,4-dichloro-phenyl)-5-methyl-1H-pyrazol-3-carboxylic acid-ethylester, 1-(2,4-dichloro-phenyl)-5-isopropyl-1H-pyrazol-3-car boxylic acid-ethylester, 5-chloro-quinolin-8-oxy-acetic acid-1-allyloxy-prop-2-yl-ester, 5-chloro-quinoxalin-8-oxy-acetic acid-methylester, 5-chloro-quinolin-8-oxy-acetic acid-ethylester, 5-chloro-quinoxalin-8-oxy-acetic acid-allylester, 5-chloro-quinolin-8-oxy-acetic acid-2-oxo-prop-1-yl-ester, 5-chloro-quinolin-8-oxy-malonic acid-diethylester, carboxyamide compound of formula (R 1> 6>-CO-N(R 1> 7>)(R 1> 8>)), or a phenyl compound of formula (IId) or (IIe); (4) an N-acylamino acid ester compound of formula (II); (5) a phenyl compound of formula (XV), (XIV) or (XIX); and (6) a phenyl-acetic acid compound of formula (XVII). Either R 1> 7>H, or F, Cl and / or Br substituted 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl, 1-4C alkoxy-1-4C alkyl, dioxolanyl-1-4C alkyl, furyl, furyl-1-4C alkyl, thienyl, thiazolyl, piperidinyl, or optionally F, Cl and / or Br or 1-4C alkyl substituted phenyl; and R 1> 8>H, optionally F, Cl and / or Br substituted 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl, 1-4C alkoxy-1-4C alkyl, dioxolanyl-1-4C alkyl, furyl, furyl-1-4C alkyl, thienyl, thiazolyl, piperidinyl, or optionally F, Cl and / or Br or 1-4C alkyl substituted phenyl; or R 1> 7>R 1> 8>optionally 1-4C alkyl substituted phenyl, furyl or annealed benzene ring; or CR 1> 7>R 1> 8>5- or 6-membered carbocyclic (substituted by 3-6C alkandiyl or 2-5C oxaalkandiyl); either R 2> 5>H, optionally cyano, OH, halogen or 1-4C alkoxy substituted 1-6C alkyl, optionally cyano or halo substituted 3-6C alkenyl or 3-6C alkynyl, optionally cyano, halogen or 1-4C alkyl substituted 3-6C cycloalkyl; and R 2> 6>R 2> 5>, optionally nitro, cyano, halo, 1-4C alkyl, 1-4C haloalkyl, 1-4C alkoxy or 1-4C haloalkoxy substituted phenyl; or R 2> 6>R 2> 5>2-6C alkandiyl (substituted optionally with 1-4C alkyl or 2-5C oxaalkandiyl); and R 1> 6>F, Cl and / or Br substituted 1-4C alkyl. [Image] [Image] [Image] [Image] - ACTIVITY : Antiparasitic; Herbicide; Insecticide; Arachnicide; Anthelmintic; Nematocide. - MECHANISM OF ACTION : None given.
Owner:BAYER IP GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products